Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for myeloma patients: experimental combo aims to keep cancer away longer

NCT ID NCT07297329

First seen Jan 07, 2026 · Last updated May 20, 2026 · Updated 20 times

Summary

This study tests whether adding an experimental drug called SCTC21C to standard chemotherapy (VRd) can help people with newly diagnosed multiple myeloma live longer without their cancer getting worse. About 292 participants who are not eligible for a stem cell transplant will be randomly assigned to receive either the standard treatment alone or the standard treatment plus SCTC21C. The main goals are to see if the combination delays disease progression and increases the chance of achieving a deep remission (minimal residual disease negativity).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beijing Chaoyang Hospital affiliated to Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 100000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.